Antibiotics: Practice MCQs

Answer: B. Aminoglycoside activity is confined to aerobic organisms, so an anaerobic environment removes their usefulness

These agents work only where oxygen is present. Their broad reputation describes breadth against aerobes, not universal cover, so an infection needing anaerobic treatment requires a different drug alongside them.

Answer: C. Gentamicin, streptomycin and tobramycin — vestibular loss that may reverse; amikacin and kanamycin — irreversible cochlear hearing loss

The split runs by drug. Gentamicin, streptomycin and tobramycin damage the vestibular apparatus and that loss is potentially reversible, whereas amikacin and kanamycin cause irreversible cochlear hearing loss.

Answer: C. They bind the 30S subunit at the A-site on 16S rRNA, causing the genetic code to be misread

Aminoglycosides bind the bacterial 30S ribosomal subunit at the A-site on 16S rRNA. The resulting misreading of the genetic code produces defective proteins, which is why the class is bactericidal rather than merely bacteriostatic.

Answer: B. Killing is concentration-dependent, so higher peak concentrations kill more effectively

Aminoglycoside killing is concentration-dependent — higher peak concentrations kill more effectively — which is the pharmacological rationale for once-daily high-dose regimens. It does not remove the need for monitoring.

Answer: A. Myasthenia gravis

The class blocks neuromuscular transmission, and in myasthenia gravis that block is both unusually prolonged and dangerous. A documented interaction with calcium channel blockers pushes the same risk higher.

Answer: B. Nephrotoxicity is generally reversible, whereas cochlear damage from amikacin or kanamycin is irreversible

Renal injury from this class generally recovers once the drug is stopped. Hearing loss of the cochlear pattern — the amikacin and kanamycin problem — does not recover. Reported frequencies run about 10 to 25% for renal toxicity and 2 to 45% for ototoxicity, and no antidote exists once either has occurred.

Answer: C. Neomycin is used orally precisely because it is not absorbed

Most aminoglycosides are poorly absorbed from the gut and are given intravenously or intramuscularly. Two members are given by mouth for exactly that reason: neomycin and paromomycin are not absorbed systemically, so their effect is confined to the bowel lumen.

Answer: B. They inhibit DNA ligation and stabilise the enzyme-DNA complex, so the trapped topoisomerase becomes the source of permanent double-stranded chromosomal breaks

The enzyme is not merely switched off — it is turned against the cell. Bacterial DNA topoisomerases are caught mid-reaction, able to cut the chromosome but no longer to rejoin it, and what would normally be a transient repair intermediate becomes fixed damage. Double-stranded breaks then accumulate faster than the organism can repair them, which is why killing follows.

Answer: A. Its label states it is not a drug of first choice for pneumococcal pneumonia, whereas levofloxacin is the agent with enhanced activity against both penicillin-sensitive and penicillin-resistant strains

Ciprofloxacin's strength lies among the gram-negative bacilli, and the pneumococcus is its weak point rather than an absolute gap — its label names the organism but tells prescribers it is not a first choice for pneumococcal pneumonia. Levofloxacin is the member whose gram-positive activity is most enhanced, extending to penicillin-resistant pneumococci, which is exactly why the two agents are not interchangeable for a chest infection.

Answer: C. Moxifloxacin's Pseudomonas activity is poor, and levofloxacin's is reduced compared with ciprofloxacin

Treating the class as uniformly anti-pseudomonal is a common error. Ciprofloxacin sits at the top for this organism, levofloxacin's action against it is diminished by comparison, and moxifloxacin is weak here — moxifloxacin's distinguishing asset is anaerobic cover instead, the reverse of the ciprofloxacin trade-off.

Answer: D. Delafloxacin

Delafloxacin stands alone here: it is the single member of the class credited with MRSA activity, and no other agent among the six approved for systemic use shares it. Moxifloxacin is the one remembered for anaerobic cover, not for resistant staphylococci.

Answer: A. Peripheral neuropathy, QTc prolongation with a risk of Torsades de pointes, aortic aneurysm and dissection, central nervous system effects, and a recognised disability syndrome

Treating the tendon warning as the whole story is a frequent slip. Nerve damage, QTc lengthening, the vascular risk of aortic aneurysm and dissection, and the persisting disability syndrome all sit alongside it, and confusion, anxiety and depression are documented central nervous system effects of the class. Taken together these warnings are why a member of this class is a weighed decision rather than a default.

Answer: B. Tendon rupture, with the Achilles tendon particularly affected and involvement frequently bilateral

Rupture of a tendon is the effect most closely identified with this class, and the Achilles is the classic site. The point students most often miss is that both sides may go, so new tendon pain or swelling calls for the drug to be stopped and assessment sought.

Answer: C. Cartilage damage and arthropathy in children, alongside a theoretical concern about fetal DNA synthesis in pregnancy

Paediatric restriction rests on the risk of damage to cartilage and the arthropathies that follow. In pregnancy the reservation is different in kind — a theoretical worry about the drug's action on fetal DNA synthesis — but both place the class in the relatively contraindicated category rather than making it a convenient oral option.

Answer: B. Mutation of the target enzymes, plasmid-mediated transfer of resistance determinants, and chromosomal change such as altered porins or over-expressed efflux pumps

Three independent routes are described: the target enzymes themselves mutate so the drug binds less well; determinants move horizontally between organisms on plasmids; and chromosomal changes cut how much drug reaches the target by altering porins or amplifying efflux. Horizontal transfer in particular lets resistance spread readily, which is a further argument for reserving the class rather than using it freely.

Answer: C. It arrives as an inert prodrug that only low-redox, ferredoxin-linked electron transport can reduce to an active form

The molecule crosses into cells doing nothing at all. Activation demands the anaerobic electron-transport machinery in which pyruvate:ferredoxin oxidoreductase supplies electrons to ferredoxin, and organisms that cannot run that chemistry leave the drug switched off.

Answer: D. Radical anions attack DNA directly, breaking strands and destroying helical structure

The active species is a short-lived radical, and the damage it does is chemical rather than enzymatic. Strands are severed and the helix loses its architecture, an injury lethal enough to make the drug bactericidal rather than merely growth-arresting. Continued reduction inside the cell also consumes drug, keeping a gradient that pulls in more of it.

Answer: B. Its useful reach is limited to obligate anaerobes and anaerobic protozoa, with aerobic bacteria essentially untouched

The breadth here runs across kingdoms rather than across oxygen requirements. Obligate anaerobes such as Bacteroides fragilis and Clostridioides difficile fall within range, as do Giardia, Entamoeba histolytica and Trichomonas vaginalis, while anything growing aerobically does not — which is why mixed infection needs a partner agent to handle the aerobic component.

Answer: A. A disulfiram-like reaction on exposure to alcohol, with flushing, a fast pulse, nausea and vomiting

Alcohol taken during a course of either agent, or shortly after one finishes, has been reported to produce the flushing, tachycardia and vomiting pattern associated with disulfiram. It is a documented basis for the standard counselling point rather than a piece of folklore, and both nitroimidazoles carry it.

Answer: C. Peripheral sensory neuropathy

Numbness and paraesthesiae from sensory nerve involvement track with how much drug has been given over time and can be slow to settle, which is why course length is the practical limit on this agent. Taste disturbance, harmless discolouration of the urine by metabolites and gastrointestinal upset appear early and carry no such implication. Rare central toxicity — ataxia, dysarthria, nystagmus, confusion or seizures — also clusters around high or extended dosing.

Answer: B. It inhibits CYP2C9, the route by which the more potent warfarin enantiomer is cleared

Blocking that particular oxidative pathway leaves more active anticoagulant in circulation, so the INR climbs while the two drugs overlap and needs closer watching. Lithium concentrations can also rise on metronidazole, and concurrent disulfiram is avoided because psychotic reactions have been associated with the combination.

Answer: C. Acquisition of nim genes whose reductase diverts the drug down a route that never yields the lethal radical

This is resistance by declining to arm the weapon rather than by destroying it: the organism processes the compound along a harmless pathway, so no DNA-damaging species is ever generated. Clinically significant resistance in B. fragilis nonetheless remains uncommon, and the same theme of reduced activation explains resistant Helicobacter pylori and refractory Trichomonas vaginalis isolates.

Answer: C. Penicillin-binding proteins, the transpeptidase enzymes of the cell wall

Every drug in this class acts on the same molecular target: the transpeptidase enzymes called penicillin-binding proteins. The beta-lactam ring acylates the enzyme's active site, and the resulting stable complex leaves the enzyme unable to finish cross-linking peptidoglycan. Neither the ribosome nor bacterial DNA is involved.

Answer: D. Human cells have no peptidoglycan cell wall, so there is no comparable target

The structure these drugs attack simply does not exist in us. Because our cells build no peptidoglycan wall, there is no equivalent enzyme for the beta-lactam to inactivate, and that structural absence — rather than any difference in absorption or metabolism — is the basis of the class's safety margin.

Answer: A. Ureidopenicillins — piperacillin

Antipseudomonal reach within this class belongs to the ureidopenicillin group, and piperacillin is its representative member. That group holds activity against Gram-negative bacilli which the aminopenicillins cannot cover, Pseudomonas aeruginosa included; the aminopenicillins list that organism as a recognised gap.

Answer: C. Methicillin resistance in staphylococci

These partner agents disable serine beta-lactamase enzymes, so they rescue a beta-lactam that would otherwise be hydrolysed. Staphylococcal methicillin resistance is a different problem entirely — the target enzyme itself has changed shape — and no amount of enzyme inhibition restores binding to an altered penicillin-binding protein.

Answer: B. Fewer than 1%, although roughly 10% carry the label

Reported and confirmed allergy diverge sharply. About one in ten US patients carries the label, yet under one percent prove truly allergic when assessed. This is why an unexamined label is treated as a caution rather than a settled fact — allergy history, validated risk assessment, skin testing and a supervised direct oral challenge can correct it.

Answer: D. Parenteral benzylpenicillin is the preferred agent across every stage

Benzylpenicillin given by injection holds preferred status for this infection at all stages of disease, not merely early or late presentations. The particular preparation and duration differ with the stage and clinical picture, but the choice of drug itself does not change.

Answer: B. Interrupted cross-linking leaves a wall that cannot resist osmotic pressure, and the organism's own autolytic processes complete the killing

Halting the final cross-linking step does more than pause growth. The partly assembled wall can no longer contain normal internal osmotic pressure, and the bacterium's own autolytic machinery finishes the job, so viability is lost and the cell lyses. The class is therefore classified as bactericidal.

Answer: C. Hepatic reactions presenting as jaundice with pale stools and dark urine

Liver injury is the drug-specific warning attached to this antistaphylococcal penicillin. The presentation to recognise combines yellowing of the skin or the whites of the eyes with pale stools and darkened urine, and it is treated as a reason to stop the medicine and seek urgent medical review.

Answer: C. The cationic drug binds the phosphate groups of anionic lipid A, displaces stabilising calcium and magnesium, and makes the outer membrane permeable

The action is physical rather than enzymatic. Electrostatic attraction pulls the positively charged molecule onto the negatively charged lipid A of lipopolysaccharide, and the divalent cations that bridge adjacent lipopolysaccharide molecules are pushed aside. The outer membrane then leaks its contents and the organism dies, a detergent-like effect that needs neither bacterial growth nor protein synthesis to work.

Answer: A. Gram-positive bacteria have no outer membrane and therefore no lipopolysaccharide target

Every step of the mechanism depends on lipid A sitting in an outer membrane. Organisms built without that membrane simply present nothing for a cationic detergent antibiotic to attack, so the gap is absolute rather than a matter of degree. Being reserved as a last-line agent says nothing about breadth of spectrum, and confusing the two is a common examination error.

Answer: D. Polymyxin B is given in active form, while colistin is administered parenterally as the inactive prodrug colistimethate sodium

Colistimethate sodium has to hydrolyse in the body before any active colistin exists, and that conversion delays and blurs the achievement of useful drug concentrations. Polymyxin B needs no such conversion, which is why it is favoured for intravenous therapy: levels arrive sooner and more predictably, and nephrotoxicity by that route is lower.

Answer: B. Nephrotoxicity

Renal toxicity is the most frequent adverse effect of the class and the reason colistin was largely abandoned after its introduction, returning to practice only when resistance closed off gentler alternatives. It can present with blood or protein in the urine, reduced urine output and, at worst, renal failure, so urea, creatinine and urine output are followed throughout treatment. Therapy is stopped if renal impairment appears, though the tubular injury commonly recovers afterwards with supportive fluid and electrolyte care.

Answer: C. Cholinesterase inhibitors are of no benefit; the drug is stopped and ventilation supported mechanically if apnoea develops

Neurological toxicity affects roughly seven in every hundred treated patients, most often as paresthesia, with dizziness, numbness, tingling and vertigo also described; mild symptoms usually settle once the drug is withdrawn. At the severe end the blockade can shut down respiration, and an anticholinesterase does nothing to reverse it — mechanical ventilation is what supports the patient if apnoea occurs. This behaviour is what distinguishes it from blockade produced by competitive neuromuscular blocking agents.

Answer: D. Proteus, Serratia, Morganella, Providencia and Burkholderia

These genera constitutively decorate their lipid A with cationic substituents such as L-Ara4N and phosphoethanolamine, through the arnBCADTEF operon and the eptB gene. The resulting loss of negative charge leaves the cationic drug with nothing to bind, so resistance is built into the organism rather than acquired under pressure. Identifying the genus is therefore enough to rule the class out.

Answer: C. It sits on a plasmid and so can move horizontally between gram-negative species

Mutations in regulatory systems such as pmrAB, phoPQ or mgrB stay locked inside the lineage that acquired them. A plasmid-carried gene travels laterally instead, and mcr-1 has done so worldwide since it was first described in Escherichia coli from pigs and meat in China in November 2015, with further variants following. Agricultural use in pig and poultry farming dominates global colistin consumption and sustains the reservoir, so this is an agricultural problem as much as a hospital one.

Answer: C. It lets them competitively inhibit dihydropteroate synthase, so bacterial folate synthesis stalls at its first step

Because the drug looks like the natural substrate, it competes for the enzyme that begins folate manufacture, and the pathway stalls there. Selective toxicity follows from the fact that human cells never run that pathway, taking preformed folate from the diet instead of assembling it from PABA, so the target simply does not exist in the host.

Answer: A. Trimethoprim blocks dihydrofolate reductase, the next enzyme in the same pathway, so the sequential double block collapses tetrahydrofolate supply

The two agents strike consecutive steps of a single pathway. With both the synthase and the reductase inhibited, the organism cannot generate tetrahydrofolate at all, and without it purines, thymidylate and several amino acids become unavailable. DNA synthesis fails, so the organism dies instead of merely pausing.

Answer: D. Stevens-Johnson syndrome or toxic epidermal necrolysis

These drugs sit among the classic causes of severe cutaneous reactions and of systemic hypersensitivity with fever, rash and organ involvement. A blistering or mucosal eruption is an emergency, the drug is stopped at once, and the whole class is then kept away from that patient permanently. Ordinary maculopapular rash is far commoner and is the usual reason a routine course is abandoned.

Answer: B. Competition with unconjugated bilirubin for albumin binding, so displaced bilirubin deposits in the basal ganglia

The hazard here is protein binding rather than the folate pathway. These drugs occupy albumin sites that unconjugated bilirubin would otherwise use, and the bilirubin set free can cross an immature blood-brain barrier and lodge in the basal ganglia, which is kernicterus. The antifolate worry in early pregnancy is a separate matter, arising from the trimethoprim component.

Answer: C. Trimethoprim competitively inhibits tubular secretion of creatinine, so the level can rise with filtration unchanged

Blocking the tubular transporter that secretes creatinine lifts the measured serum level without any change in true glomerular filtration, a well-recognised artefact of this combination. It is not a licence to ignore the result, though, because genuine injury from interstitial nephritis or from sulfonamide crystals still has to be excluded when the rise is large.

Answer: D. Plasmid-carried sul genes encoding a dihydropteroate synthase variant with low affinity for the drug

An enzyme the drug barely binds lets folate manufacture carry on regardless, and the genes encoding it travel on plasmids, which is what makes this the leading acquired route. Two other escapes exist: overproducing the natural substrate simply outcompetes a competitive inhibitor, and organisms able to scavenge ready-made folate or thymidine from their surroundings sidestep the blocked pathway altogether.

Answer: A. Sulfamethoxazole inhibits CYP2C9 and also displaces warfarin from protein binding, so both routes push the INR upward

Two mechanisms operate at once. The enzyme that clears the more potent S-isomer of warfarin is inhibited, and warfarin is simultaneously pushed off its plasma protein binding sites. A rising INR and a real bleeding hazard follow, which is why this pairing is a standing examination scenario.

Answer: B. Enough of the sulfadiazine moiety crosses burned skin, and increasingly so as the treated area grows

Damaged skin is a poor barrier, and the larger the surface treated the more drug crosses it. That is sufficient to reproduce the reactions expected from systemic exposure, including haemolysis in glucose-6-phosphate dehydrogenase deficiency and transient leukopenia, so a topical route is not automatically a systemically safe one.

Answer: B. Spectrum of coverage against gram-positive and gram-negative organisms, together with when each agent was discovered

The generation label is a shorthand for two things at once: which organisms an agent reaches across the gram-positive and gram-negative divide, and the historical order in which the drugs appeared. It is not a statement about how a drug is given or cleared.

Answer: D. Cefazolin, because it covers the gram-positive skin flora responsible for most surgical site infections

The organisms that seed most post-operative wound infections are gram-positive skin residents, and the first-generation agent cefazolin is the one specifically preferred to cover them before surgery. Broader later-generation agents are not the answer here.

Answer: A. Only ceftazidime carries that activity within the third generation

Antipseudomonal reach is a property of a single member rather than the whole tier. Ceftazidime is the third-generation drug that covers this organism; its stablemates such as ceftriaxone and cefotaxime extend gram-negative range but do not. Cefepime in the fourth generation also reaches Pseudomonas.

Answer: C. It covers MRSA and penicillin-resistant pneumococci but has no Pseudomonas aeruginosa activity

Being newest does not mean widest. This fifth-generation agent adds two things the earlier tiers lack — methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae — while leaving Pseudomonas aeruginosa uncovered, which is a listed gap for it.

Answer: D. Cefepime

Neurotoxic effects of this pattern are the signature problem of the fourth-generation agent cefepime, and they surface in overdose or when the dose has not been scaled to reduced renal clearance. That link is precisely why renal function governs how this drug is used.

Answer: A. Because ceftriaxone and calcium can precipitate together

The problem is a physical one: the drug and calcium can come out of solution together, and that precipitation risk is why this agent is barred in jaundiced newborns and in very young infants who are due calcium-containing intravenous products. It is a frequently examined contraindication.

Answer: C. Ceftriaxone, cefotaxime, ceftazidime and cefepime

Four members of the class cross into the central nervous system well enough to be treatment options for meningeal infection, and they span the third and fourth generations. The first-generation agents penetrate the cerebrospinal fluid poorly, so they are not alternatives here.

Answer: B. It is greatest with first- and second-generation agents and minimal from the third generation onward

Shared R-group chemistry, not the beta-lactam ring alone, drives the overlap, so the risk clusters in the earlier agents and falls away in the later ones. A separate point worth remembering is that the allergy label itself is often wrong, since fewer than one percent of labelled patients prove truly allergic on assessment. Anaphylaxis to a beta-lactam nonetheless remains an absolute bar.

Answer: B. Bound to calcium, it inserts its lipophilic tail into the gram-positive cell membrane and depolarizes it through potassium efflux

Calcium is part of the mechanism rather than an incidental cofactor: complexed with calcium the molecule behaves like a cationic peptide drawn to the bacterial membrane, where its decanoyl tail anchors and the inserted molecules oligomerize. Potassium then leaks out, membrane potential collapses, and synthesis of DNA, RNA and protein arrests. Killing is rapid and concentration-dependent, and notably the cell dies intact rather than bursting.

Answer: D. Pulmonary surfactant binds the drug and inactivates it in the alveoli

The organism is susceptible in the laboratory but the drug never gets to act in the airspaces, because surfactant lining the alveoli sequesters and neutralises it. That is why trials in pneumonia failed and why the prohibition holds irrespective of what the susceptibility report says. Vancomycin or linezolid are the agents turned to for MRSA pneumonia.

Answer: A. Because the infection is seeded through the bloodstream, where the drug is active, rather than being an airspace pneumonia

The distinction is anatomical. A right-sided valve infection lives in the circulation and the drug reaches embolic lesions the same way, so surfactant never stands between drug and organism. Airspace infection is the specific setting the drug cannot treat, and generalising the prohibition to any chest involvement is a common error.

Answer: C. Creatine phosphokinase

Muscle injury is the signature adverse effect, spanning silent enzyme elevation through to painful or weak muscles with markedly raised creatine phosphokinase. The enzyme is checked before treatment and at least weekly during it, more often where renal clearance is reduced or a statin is being taken concurrently, since both raise the risk. Temporarily suspending a statin during a course is a recognised consideration, and the antibiotic is withdrawn when myopathic symptoms accompany a significant enzyme rise.

Answer: B. Interference with certain recombinant thromboplastin reagents, producing a falsely elevated result

This is an artefact of the assay, not evidence of a bleeding tendency. Repeating the sample near the drug trough, or running it with a different reagent, resolves the discrepancy and avoids treating a coagulopathy that does not exist. Notably, the drug does not lyse the organisms it kills, so a lysis-driven coagulation cascade is not the explanation either.

Answer: D. Gram-positive organisms only, including MRSA and vancomycin-resistant enterococci

Activity stops at the gram-positive boundary — the bulky lipopeptide cannot get past a gram-negative outer membrane — so any gram-negative cover has to come from a separate agent. Within gram-positives it reaches Staphylococcus aureus including methicillin-resistant strains, beta-haemolytic streptococci and enterococci including vancomycin-resistant Enterococcus faecium, which is what makes it a valuable alternative when vancomycin is unusable outside the lung.

Answer: C. By remodelling the cell membrane, through changes such as mprF mutations, so the calcium-bound cationic drug is repelled

Since the target is the membrane itself, resistance means changing the membrane. Altered charge and phospholipid composition repel the calcium-bound drug and reduce how much of it inserts. Reduced susceptibility has been reported to appear during treatment, particularly in deep-seated or high-inoculum infection where cultures stay positive, so persistent bacteraemia is a reason to repeat cultures and susceptibility testing rather than assume the drug is still working.

Answer: D. MurA, the UDP-N-acetylglucosamine enolpyruvyl transferase

The drug's epoxide ring opens onto an active-site cysteine and forms a dead-end adduct, permanently disabling the enzyme that transfers enolpyruvate from phosphoenolpyruvate onto UDP-N-acetylglucosamine. That reaction commits the sugar to the peptidoglycan route and is the earliest wall-building step any antibiotic attacks, far upstream of where beta-lactams and glycopeptides work.

Answer: B. By carriage on the GlpT and UhpT transporters, whose natural substrates it mimics

The molecule resembles glycerophosphate and glucose-6-phosphate closely enough to be picked up by the carriers meant for those sugars, so entry is active rather than incidental. Relying on somebody else's transport system is a liability, and it is precisely why the commonest form of resistance is a mutant that stops making the carrier.

Answer: C. It carries no beta-lactam ring, and MurA is not something a beta-lactamase can act on

Those enzymes exist to hydrolyse a particular chemical ring, and this compound simply does not have one. Because the target sits at the start of peptidoglycan synthesis rather than among the penicillin-binding proteins, an organism well defended against penicillins and cephalosporins is no better protected here — the reason a drug from the 1960s became newly important in the multidrug-resistance era.

Answer: A. Uncomplicated lower urinary tract infection in women

The labelled role is acute uncomplicated cystitis caused by susceptible Escherichia coli or Enterococcus faecalis, where the pathogen sits in bladder urine and the drug is excreted unchanged into exactly that compartment. Concentrations in renal tissue are not adequate, so infection that has climbed above the bladder lies outside what this product can do, and persistent symptoms call for culture and a different agent rather than a repeat sachet.

Answer: D. Excretion of unchanged drug into urine, where concentrations stay therapeutic for two to four days

Very little of the compound is metabolised; it leaves the body intact by the renal route and remains at active levels in urine across several days. That sustained bladder exposure is what allows one sachet to match the cure rates reported for a seven- to ten-day course of another first-line agent, so the regimen is a consequence of the pharmacokinetics rather than a marketing convenience.

Answer: B. Mutational loss or downregulation of the GlpT or UhpT uptake transporters

Shutting the door is easier than changing the lock, so mutants that no longer express the uptake carriers dominate, although such isolates often pay a fitness penalty in the urinary tract. Mutation of the MurA active-site cysteine, which prevents the covalent adduct forming, and glutathione-conjugating enzymes of the FosA family are the other described routes; plasmid spread of the latter is the stewardship worry.

Answer: C. Metoclopramide lowers fosfomycin serum concentrations and urinary excretion, while cimetidine leaves its pharmacokinetics unchanged

Hurrying material through the gut leaves less opportunity for absorption, and for an agent whose entire strategy rests on one well-absorbed dose that shortfall can mean failure; other promotility drugs may behave the same way. The histamine H2 blocker is the documented negative examiners like to pair with it, having no measurable effect on the drug's handling.

Answer: B. Inhibition of bacterial DNA-dependent RNA polymerase, arresting transcription

The drug binds the microbial DNA-dependent RNA polymerase and sterically obstructs the path of the elongating transcript, so RNA synthesis halts. That is transcription rather than translation, one step upstream of where the ribosomal agents work. The enzyme attacked is the bacterial one, which is why the human polymerase is spared, and the arrest kills rather than merely suppressing growth.

Answer: D. Resistance is a single-step event: rpoB point mutations account for the overwhelming majority of resistant isolates

The rpoB gene encodes the beta subunit of RNA polymerase, and a point mutation there reshapes the binding site so the drug no longer attaches. Nearly every resistant Mycobacterium tuberculosis isolate carries such a mutation, and monotherapy is precisely the condition that selects for it, so companion agents are built into the regimen to avert that outcome.

Answer: A. Rifampin potently induces CYP3A4 and several other P450 enzymes, accelerating clearance of co-administered drugs

Induction of CYP3A4, CYP2C9, CYP2C19, CYP2C8 and CYP1A2 speeds the metabolism of a wide range of co-medications, so their effect falls away. Contraceptive failure, weakened warfarin anticoagulation and falling protease inhibitor concentrations are the three consequences worth committing to memory, and every concurrent drug deserves an interaction check.

Answer: C. An expected, dose-dependent and harmless property of the drug itself

Tears, sweat, saliva, urine and faeces all take on the colour, its intensity tracks the dose, and no harm follows. Warning the patient in advance is what matters, since soft contact lenses can be stained and an uncounselled patient may abandon treatment over it. Liver injury is a genuinely separate risk, tracked with liver enzymes rather than by the colour of urine.

Answer: B. Rifabutin induces P450 enzymes far more weakly, with a relative potency around 0.4 against rifampin at 1.0

Rifampin is the strongest inducer of the family and can drive protease inhibitor concentrations down far enough for the pairing to be contraindicated. Its weaker relative sits at roughly 0.4 on that same scale, which is what makes it the substitute in HIV care, where it is used largely to prevent Mycobacterium avium complex disease. It is not free of hazard, though, since uveitis is its rare but potentially severe signature.

Answer: D. It is essentially non-absorbed, with under 0.4% detectable in blood or urine, so it acts only in the gut lumen

Non-absorption is engineered rather than accidental: luminal concentrations run high while blood levels stay negligible. That is precisely why its approved uses are all gastrointestinal, covering travellers’ diarrhoea caused by noninvasive Escherichia coli, reduction of overt hepatic encephalopathy recurrence, and irritable bowel syndrome with diarrhoea, and why invasive febrile dysenteric illness falls outside its remit.

Answer: C. A dose-independent hypersensitivity reaction, more frequent with intermittent or prolonged administration

This family of reactions does not track the dose at all. Flu-like symptoms sit alongside thrombocytopenia, haemolysis and renal failure in the same hypersensitivity group, and they become commoner when the drug is given in an interrupted pattern or carried on over an extended period. Recognising the pattern and escalating, rather than rechallenging blindly, is the point being examined.

Answer: A. A half-life longer than that of rifampin and rifabutin

It outlasts the other members of the family in the body, and that alone is the basis for once- or twice-weekly administration in tuberculosis regimens. On enzyme induction it is not innocent either, since its potency lies between rifabutin’s and rifampin’s. Minor transient aminotransferase rises are reported in 2 to 7% of patients on long-term therapy.

Answer: C. They act at the 30S subunit so that aminoacyl-tRNA cannot attach to the mRNA-ribosome complex

Inhibition happens at the small ribosomal subunit. With the charged tRNA unable to dock at the mRNA-ribosome complex, the growing chain never receives its next amino acid, translation stalls, and the organism cannot replicate.

Answer: A. Spectrum and killing effect are independent properties: this class reaches gram-positives, gram-negatives, spirochetes, chlamydia and rickettsia yet only arrests growth

How wide a drug's coverage runs says nothing about whether it kills. These agents reach an impressively wide range of organisms, spirochetes, chlamydia and rickettsia among them, and still only hold multiplication in check, so the host's own defences finish the job.

Answer: D. They supply multivalent cations that chelate the drug and severely impair its absorption

Aluminium, calcium, iron and magnesium bind these molecules directly. The complex that forms is poorly taken up, and the loss of absorption is severe rather than marginal, which is why the interval between the drug and milk, antacids or iron preparations is a real clinical variable rather than a footnote.

Answer: B. They deposit in developing teeth and bone, producing permanent yellow-brown discolouration and impaired bone growth, with maternal liver toxicity a further concern in pregnancy

Deposition into mineralising tissue is the problem. A child exposed before roughly 8 years old can be left with permanently stained teeth and slowed skeletal growth, and pregnancy adds two further recorded risks: hepatotoxicity in the mother and discolouration of the fetus's teeth.

Answer: C. Considered safe, because calcium in milk chelates the drug and limits how much reaches the infant

This is the counter-intuitive one. The same chelation chemistry that ruins absorption when the drug meets dairy turns protective during lactation — calcium in the milk ties the drug up, infant exposure stays low, and the class is regarded as acceptable here even though pregnancy rules it out.

Answer: A. Minocycline

Minocycline carries the greatest hepatic risk of the class and sits among the ten commonest causes of drug-induced liver injury recorded in the United States, characteristically after a long latent period and with autoimmune features. Doxycycline can also injure the liver, but its latency is shorter, roughly one to sixty days, and its enzyme patterns are variable.

Answer: D. Ribosomal protection proteins, efflux pumps, and modification of the drug itself

Three routes are recognised rather than one. Protection proteins keep the ribosome translating despite high drug concentrations, transmembrane transporters pump the drug back out of the cell, and a less studied modification pathway alters the molecule. The genes responsible usually sit on plasmids or transposons, so they pass between bacteria easily and resistance spreads quickly once established.

Answer: B. As the sole member of the glycylcycline subclass

The class is grouped by origin and generation: the original natural agents, the semi-synthetic derivatives that dominate current practice, a recent group that includes omadacycline, eravacycline and sarecycline, and the glycylcyclines — a subclass whose only occupant is tigecycline.

Answer: B. Dihydrofolate reductase, so dihydrofolate is not reduced to tetrahydrofolate

Trimethoprim occupies bacterial dihydrofolate reductase as a competitive inhibitor, halting the reduction of dihydrofolate to its active tetrahydrofolate form. Without tetrahydrofolate the organism cannot assemble purines, so DNA and protein production stall. The step before this one, from para-aminobenzoic acid to dihydrofolate, belongs to sulfamethoxazole and dihydropteroate synthase.

Answer: D. Two consecutive steps of one pathway are blocked, which yields bactericidal activity in certain settings such as the urinary tract

The synergy is positional rather than pharmacokinetic. Sulfamethoxazole starves the pathway of dihydrofolate by inhibiting dihydropteroate synthase, and trimethoprim shuts down the reductase that would consume whatever dihydrofolate remains. Interrupting the pathway at two consecutive points converts two bacteriostatic drugs into a combination that kills in certain settings, the urinary tract among them.

Answer: D. Blockade of the epithelial sodium channel in the distal nephron, exactly as amiloride does

The drug behaves like a potassium-sparing diuretic at the distal nephron, closing the epithelial sodium channel and so removing the electrochemical gradient that drives potassium into the urine. Renal impairment, older age, and co-prescription of ACE inhibitors, angiotensin receptor blockers or spironolactone all magnify the resulting rise in potassium.

Answer: C. Inhibition of tubular creatinine secretion, giving a reversible and artefactual rise

Creatinine is cleared partly by tubular secretion, and trimethoprim blocks that secretion. Serum creatinine therefore climbs and any creatinine-based estimate of filtration falls, while true filtration is untouched; the change reverses once the drug stops. The combination product can add roughly a further tenth through interference with the Jaffe alkaline picrate assay. None of this excludes genuine kidney injury, which still has to be assessed on its own merits.

Answer: B. Folinic acid (leucovorin), because it enters the pathway beyond the blocked reductase step

The blockade sits at the reduction of dihydrofolate, so supplying more of the substrate upstream achieves nothing. Folinic acid bypasses the inhibited enzyme and is what is used, under specialist direction, until haematopoiesis recovers. Folic acid has a separate role as supplementation alongside exposure during pregnancy, which is a different question altogether.

Answer: A. Because its affinity for the bacterial enzyme is far greater than for the human one, a margin that is large but quantitative rather than absolute

Selectivity here is a matter of degree, not of a target that humans lack. The bacterial and human active sites differ and the drug binds the bacterial version much more tightly, but the margin has limits — which is precisely why folate deficiency, megaloblastic anaemia and first-trimester teratogenic risk remain real adverse outcomes.

Answer: C. Congenital malformations including cardiac defects, cleft lip or palate and neural tube defects

Antagonising folate during organogenesis produces exactly the pattern of defects one would predict, and an excess of cardiac, orofacial cleft and neural tube anomalies is reported after exposure in the first trimester. Any use in that window is therefore an explicit risk-benefit judgement by the treating clinician, with folic acid supplementation recommended if treatment goes ahead.

Answer: A. Plasmid-encoded variant forms of dihydrofolate reductase and dihydropteroate synthase that the drugs no longer inhibit

Resistance is achieved by swapping the target rather than by destroying the drug: plasmids carry genes for altered versions of both enzymes that the antifolates cannot inhibit, with efflux and reduced permeability contributing as well. Background resistance among urinary gram-negatives such as Escherichia coli and Klebsiella pneumoniae is common enough that local antibiogram data, not habit, should govern empiric choice.

Answer: C. It blocks renal metabolism of imipenem, lengthening the drug's half-life

The partner compound is not an antibacterial at all. Its job is pharmacokinetic: by preventing imipenem from being broken down in the kidney it extends how long the drug persists. Beta-lactamase inhibition is a different concept entirely, and the other three carbapenems need no such partner because they withstand dehydropeptidase-1 on their own.

Answer: A. Ertapenem, because its half-life is around 4 hours rather than the roughly 1 hour of the others

Among the four agents only one has a meaningfully longer elimination half-life — roughly four hours against about an hour for imipenem, meropenem and doripenem — and that difference is what permits a single daily administration. Dehydropeptidase-1 stability is shared by three of the four and does not by itself change dosing frequency.

Answer: D. A fused beta-lactam ring that withstands most beta-lactamases

These drugs are still beta-lactams and still act on penicillin-binding proteins, but their ring is fused in a way that most bacterial beta-lactamases cannot cleave. That enzymatic durability is the whole basis of the class's exceptional breadth, and it is also why the class is generally kept in reserve for serious or resistant infection.

Answer: B. Most methicillin-resistant staphylococci resist carbapenems, because the resistance lies in an altered penicillin-binding protein rather than an enzyme

Breadth against beta-lactamases does not help when the target itself has changed. Methicillin resistance in staphylococci rests on a modified penicillin-binding protein, so a drug that survives enzymatic attack still cannot bind. The class does cover streptococci, enterococci, staphylococci and Listeria, but methicillin-resistant strains sit outside that cover.

Answer: D. Class B zinc-dependent metallo-beta-lactamases such as NDM

The zinc-dependent enzymes destroy the whole beta-lactam family with one exception, and that exception is aztreonam — which is precisely why aztreonam stays on the table when an organism carries NDM, IMP or VIM. Class A serine enzymes, KPC among them, do hydrolyse aztreonam as well as the penicillins, cephalosporins and carbapenems.

Answer: A. Loss of porin channels and active efflux of the drug

Resistance to this class is not always a matter of an enzyme. Losing the channel proteins the drug uses for entry cuts how much reaches the target, and pump systems export what does get in. These routes typically have to act alongside a carbapenemase before high-level resistance emerges, so the presence of one does not exclude the other.

Answer: C. All four agents are poorly absorbed from the gut and must be given parenterally

None of the available agents survives the oral route well enough to be useful, so every one of them is delivered by injection or infusion. The practical consequence is that a course cannot be stepped down to tablets within this class, which shapes how such courses are planned from the outset.

Answer: B. Meropenem

Several members of the class are used for hospital-acquired infections such as pneumonia, intra-abdominal infection and urinary tract infection. Meningeal infection is the setting singled out for meropenem, whose central nervous system penetration is described as adequate for that use.

Answer: C. They bind the 50S subunit and stop peptidyltransferase adding further amino acids to the growing chain

The target is the large half of the bacterial ribosome. Once a macrolide occupies it, peptidyltransferase can no longer extend the nascent peptide, translation stalls, and the organism cannot build the proteins it needs. Because ribosomes are so highly conserved between species, this single target gives the class its breadth.

Answer: B. They arrest growth at usual doses; killing may appear at elevated doses but is inconsistent enough that it should not be relied on

Ordinary exposure halts multiplication rather than killing the organism. Higher exposure can tip the effect towards killing, but that behaviour is unreliable, so in practice the class is treated as growth-arresting rather than lethal.

Answer: B. Every member lengthens QT and QTc, with erythromycin at the top of the risk gradient and azithromycin at the bottom

All three lengthen both intervals, so none of them is a QT-neutral option. What differs is degree: the risk runs highest with erythromycin and lowest with azithromycin. The consequence that matters is Torsades de Pointes and other ventricular arrhythmias.

Answer: D. Azithromycin reaches respiratory gram-negatives such as Haemophilus influenzae and Moraxella catarrhalis better than erythromycin, is less active against streptococci, sits lowest of the three for QT risk, and does not inhibit CYP3A4

The two agents differ in exactly the respects an exam tests. Azithromycin was derived from erythromycin with improved gram-negative reach, gives up some streptococcal potency, and sits at the bottom of the class QT gradient. Interactions do not follow the same order: clarithromycin is the strong CYP3A4 inhibitor, erythromycin a moderate one, and azithromycin does not inhibit the enzyme at all.

Answer: C. Mycoplasma pneumoniae, Legionella and Chlamydia pneumoniae, because none of them builds the cell wall a beta-lactam needs as a target

Acting at the ribosome rather than the cell envelope is what lets this class reach the atypical pneumonia pathogens. A cell-wall agent has nothing to attack in organisms that lack a wall, which is precisely the gap a macrolide fills.

Answer: B. It abolishes activity of macrolides, lincosamides and streptogramins simultaneously

Methylating the ribosomal RNA alters a site that three separate classes depend on, producing the MLS-B phenotype. One determinant therefore costs three treatment options at once, and transposable elements spread the responsible genes — so switching to a lincosamide is not the safe fallback it looks like. The change can arise by plasmid-mediated or chromosomal routes.

Answer: A. Congenital long QT syndrome type 2, or current treatment with a Class Ia or Class III antiarrhythmic

An already prolonged QT interval or the congenital type 2 long QT phenotype is an absolute bar, and antiarrhythmic therapy in the Class Ia or Class III groups is a situation in which the class should be avoided. Stacking a QT-prolonging antibiotic onto either raises the arrhythmia risk further. The other three backgrounds carry no comparable class-specific concern.

Answer: C. Agonist action at the motilin receptor, a direct pharmacological effect on gut motility

Gastrointestinal upset here is a pharmacological action rather than mere intolerance: these drugs stimulate motilin receptors, which is also why erythromycin finds a separate use as a prokinetic agent. Loss of commensal gut flora, which any antibiotic causes, adds to the nausea, vomiting, abdominal pain and diarrhoea.

Answer: B. Bacterial isoleucyl-tRNA synthetase

Part of the molecule imitates isoleucine well enough to occupy the amino-acid binding site of the enzyme that charges the matching transfer RNA. With that pool depleted, translation stalls wherever an isoleucine codon appears, and bacterial RNA synthesis is obstructed alongside protein production.

Answer: C. Drug reaching the circulation is rapidly de-esterified to monic acid, which has no antibacterial activity

Systemic exposure converts the compound almost immediately into an inactive breakdown product, so useful concentrations exist only at the surface where it is applied. Invasive staphylococcal disease therefore has to be treated with an agent from a different class, however attractive this drug's activity against resistant staphylococci looks on paper.

Answer: A. Methicillin resistance rests on altered penicillin-binding proteins, which are irrelevant to an isoleucyl-tRNA synthetase inhibitor

Resistance is target-specific, and the machinery altered in methicillin-resistant strains is not the machinery this drug attacks. No other antibiotic in clinical use inhibits the same enzyme, so nothing acquired against beta-lactams, macrolides, aminoglycosides or glycopeptides carries over; an isolate only fails to respond if it has separately picked up a mupirocin-specific mechanism.

Answer: D. Bacteriostatic at low concentrations and bactericidal at the higher ones achieved by topical application

The label is not fixed but follows exposure. Small amounts merely hold growth in check, whereas the far greater concentrations reached on skin and nasal mucosa actually kill the organism, which is exactly why the distinction is worth asking about for a drug applied directly to the site.

Answer: D. A plasmid-borne mupA gene supplying an alternative isoleucyl-tRNA synthetase that the drug cannot inhibit

This is a complete bypass rather than weakened binding: the organism simply provides a second version of the enzyme over which the drug has no hold, so piling on more concentration achieves nothing. Because the gene travels on transferable plasmids it can move between staphylococci, and it is the recognised explanation for a carrier who remains positive after decolonization. The chromosomal mutation route, by contrast, lifts the inhibitory concentration only slightly and topical levels often still exceed it.

Answer: B. It roughly halves the odds of S. aureus surgical site infection

Clearing carriage from the nose before an operation, with or without a chlorhexidine body wash, cuts the odds of a staphylococcal infection at the surgical site by around half. That measured effect is why the practice belongs to pre-surgical prevention bundles rather than being regarded as an optional skin remedy.

Answer: B. The vehicle can be absorbed through damaged skin and is potentially nephrotoxic

The concern belongs to the base, not to the antibiotic dissolved in it. Spread across large areas of broken skin the glycol carrier can be taken up, and since it is cleared renally and carries nephrotoxic potential, extensive application is cautioned against where kidney function is already impaired.

Answer: B. It binds reversibly within the 50S subunit and blocks peptide-bond formation between aminoacyl- and peptidyl-tRNA

The drug attaches reversibly to the large ribosomal subunit, at a stretch of 23S rRNA close to the peptidyl-transferase centre. With the transfer step obstructed, functional protein output falls and bacterial growth is suppressed.

Answer: C. Anaerobic activity says nothing about aerobic Gram-negative bacilli, and Enterobacterales remain an important gap

Anaerobic reach and aerobic Gram-negative reach are separate questions. Several anaerobic Gram-negative species are covered, yet the aerobic Gram-negative bacilli are not, and treating one as evidence of the other is a classic error. Enterococci and resistant staphylococci or streptococci are further gaps.

Answer: B. Clostridioides difficile-associated diarrhoea and pseudomembranous colitis, driven by loss of normal intestinal microbial diversity

Marked disturbance of the gut microbiota strips away colonisation resistance, letting toxin-producing C. difficile expand and injure the colon. The spectrum runs from diarrhoea through to fulminant disease that may end in toxic megacolon, colectomy or death, so significant new diarrhoea during or after exposure warrants prompt medical assessment rather than antimotility self-treatment.

Answer: D. Biliary excretion of drug and metabolites, which delivers high intestinal exposure

Clearance through the bile means the colon sees substantial drug, and that intestinal exposure is what places selection pressure on the resident flora and favours C. difficile. Oral absorption is in fact rapid and substantial, and central nervous system penetration, though genuinely poor, has no bearing on the gut.

Answer: A. Whether an inducible erm gene is present that routine susceptibility testing can miss

An organism carrying an inducible erm determinant can read as susceptible on a standard plate, because the methylase is only switched on once macrolide exposure induces it. Methylation of 23S rRNA then follows and clinical failure results, which is why the D-zone method is used to expose this MLS-B phenotype when erythromycin resistance is already evident.

Answer: C. Shutting down translation can reduce the organism's output of exotoxins

Exotoxins are proteins, so an agent that halts translation can lower how much toxin the organism makes. That is the rationale for adding it in invasive Streptococcus pyogenes disease and in clostridial myonecrosis — an adjunct alongside definitive antimicrobial, surgical and supportive management under specialist direction, never a solo treatment.

Answer: D. erm-mediated methylation modifies a 23S rRNA region whose binding sites overlap for all three classes

The three classes converge on an overlapping stretch of ribosomal RNA, so methylating it removes the docking site for all of them at once and produces the shared MLS-B phenotype, either constitutively or inducibly. Modifying enzymes and efflux do contribute to lincosamide resistance, but they are separate mechanisms and do not explain the cross-class pattern.

Answer: B. Hepatic metabolism dominates, mainly via CYP3A4 with a smaller CYP3A5 contribution

The liver handles most of the drug, with CYP3A4 as the principal enzyme, which is why strong inhibitors or inducers of that pathway can shift exposure. Absorption after an oral dose is rapid and substantial and food has little effect on the total absorbed, while distribution into tissue and abscesses is wide but central nervous system penetration is unreliable.

Answer: D. A single, monocyclic beta-lactam ring that is not fused to a second ring

Penicillins, cephalosporins and carbapenems all present their beta-lactam ring attached to a second ring; the monobactam scaffold carries just the one. Aztreonam, the agent that represents this class in practice, was originally obtained from Chromobacterium violaceum.

Answer: A. It binds penicillin-binding proteins, so cell-wall synthesis is inhibited and bacterial growth falls

Despite its unusual single-ring scaffold, aztreonam works in the conventional beta-lactam way. It attaches to the transpeptidases that cross-link peptidoglycan, and once wall construction is blocked the organism's growth declines.

Answer: C. Gram-positive organisms and anaerobes

This drug's reach stops at aerobic gram-negative bacilli, which is a much narrower profile than a carbapenem offers. Anything gram-positive and anything anaerobic requires a second agent, so relying on aztreonam alone in a mixed abdominal picture leaves a gap.

Answer: B. Class B metallo-beta-lactamases such as NDM, IMP and VIM

The zinc-dependent class B enzymes dismantle the entire beta-lactam family with a single exception, and that exception is aztreonam. It is the whole reason a narrow, elderly agent still earns a place when NDM, IMP or VIM is present.

Answer: C. Class A serine carbapenemases, KPC among them, hydrolyse aztreonam as readily as penicillins, cephalosporins and carbapenems

The drug does survive many beta-lactamases and specifically escapes the class B enzymes, but that immunity is not general. Serine carbapenemases of class A take it apart just as they take apart the fused-ring agents, so the exception applies to one enzyme class only.

Answer: B. Parenterally, by intravenous or intramuscular injection, with an inhalational formulation also available

Systemic therapy with this molecule means injection, either into a vein or into muscle. A separate inhaled preparation delivers the same drug straight to the airway, so two routes exist and neither of them is swallowing a tablet.

Answer: B. The D-alanyl-D-alanine end of the peptidoglycan precursor

The drug latches onto the peptide terminus of the wall precursor itself rather than onto an enzyme. With D-alanyl-D-alanine occupied, glucosyltransferase — peptidoglycan synthase — is inhibited, so neither elongation nor cross-linking of the polymer can proceed and the organism dies.

Answer: A. The mecA gene product PBP2a lowers affinity for beta-lactams, and vancomycin does not act on a penicillin-binding protein at all

Methicillin resistance rests on mecA, which generates the transpeptidase PBP2a and reduces the organism's affinity for beta-lactams. A glycopeptide never touches that enzyme, so the change is simply beside the point, and intravenous vancomycin remains the agent of choice for most methicillin-resistant infection in hospitalised patients.

Answer: C. Oral therapy is required for intestinal infection because intravenous vancomycin penetrates the colon poorly

Under a tenth of a swallowed dose is absorbed, so oral drug stays in the gut where colonic infection sits. Delivered into a vein, the same molecule reaches the bloodstream but barely reaches the colon, which is why that route fails against C. difficile.

Answer: D. Vancomycin flushing syndrome, a reaction to infusion rate rather than a true allergy

Onset four to ten minutes after an infusion begins, with that face, neck and upper-torso distribution, is the classic picture, and the speed of administration is what provokes it. Recording it as a drug allergy wrongly removes an antibiotic the patient may need. DRESS and Stevens-Johnson syndrome are separate and less common cutaneous events reported with this drug.

Answer: D. Trough concentrations above 15 mg/L

Three things push renal risk upward: troughs running above 15 mg/L, other nephrotoxic agents given alongside, and kidney impairment that was already present. Renal function is accordingly checked before, during and after a course, with particular emphasis beyond the age of 65. Oral therapy sits outside this concern because so little of the drug is absorbed.

Answer: C. Dalbavancin, oritavancin and telavancin

These three are semisynthetic macromolecules built around the vancomycin structure, and they hold activity against gram-positive organisms including MRSA. Treating them as vancomycin under other names misses the point that they were engineered with deliberately different properties.

Answer: A. Prolonged or inappropriate treatment with vancomycin

Excessive and unnecessarily long exposure is what selects these organisms out, so the countermeasure is stewardship and adherence counselling rather than any pharmacological trick. Enzymatic destruction is not the issue: a beta-lactamase does nothing to a drug that carries no beta-lactam ring and binds D-alanyl-D-alanine instead.

Answer: B. Sporadic hVISA, VISA and VRSA infections may fail to respond to glycopeptide therapy

Susceptibility cannot be assumed even within S. aureus. Isolates with hetero-intermediate, intermediate or frank resistance appear sporadically and may not respond, which is why trough levels are followed and an alternative agent is considered when an organism fails to improve.

Answer: C. At the 23S rRNA of the 50S subunit, preventing a functional 70S initiation complex from assembling

The binding site sits on the 23S rRNA component of the large subunit, and while the drug is there the two subunits cannot come together into a working 70S initiation complex. Translation is therefore stopped before the first peptide bond rather than interrupted part-way through, which is what makes this class mechanistically unlike every other ribosomal agent.

Answer: D. It is a reversible, non-selective inhibitor of monoamine oxidase

Monoamine oxidase is the enzyme that degrades serotonin, and linezolid switches it off reversibly and without selectivity. Adding a serotonergic agent on top lets serotonin accumulate, so SSRIs, SNRIs, tricyclics and MAOIs are what to look for on the medication list before treatment starts. The same enzyme block explains why a heavy tyramine load from aged or fermented food can produce a pressor reaction.

Answer: B. Generally bacteriostatic against staphylococci and enterococci, with bactericidal activity described against streptococci

The label depends on which organism is in front of you. Staphylococci and enterococci are held in growth arrest, whereas streptococci are reported to be killed. Since proteins already made are left untouched and no lethal misreading is introduced, arrest is the default outcome, and bacteriostatic remains the accepted classification even though behaviour against enterococci in patients is argued over.

Answer: A. The class is a gram-positive specialist with no useful role against gram-negative pathogens

Its clinical territory is deliberately narrow: resistant gram-positive disease, chiefly MRSA and vancomycin-resistant enterococci, with nothing to offer against gram-negative pathogens. The route distractor fails too, since linezolid can be given intravenously as well as by mouth.

Answer: D. Peripheral and optic neuropathy

Marrow suppression generally recovers after withdrawal, and the acidosis often settles quickly once the drug is stopped as well. Nerve and optic involvement is the outlier, because recovery there is slow and the deficit may prove permanent.

Answer: C. Inhibition of mitochondrial protein synthesis, because mitochondrial ribosomes closely resemble bacterial ones

Human mitochondria run ribosomes similar enough to bacterial ones that the drug throttles them too. That injury is the accepted origin of the acidosis, which characteristically appears somewhere between one and eight weeks into treatment, can be fatal, and frequently clears rapidly after the antibiotic is withdrawn. A mitochondrial DNA polymorphism, A2706G, has been reported in patients who appear predisposed.

Answer: B. Oral bioavailability is essentially complete, so exposures by either route are equivalent

Absorption approaches 100%, so a tablet delivers what an infusion delivers. That single pharmacokinetic fact is what allows resistant gram-positive infection to be treated by mouth, or stepped down from a drip, instead of tethering the patient to intravenous access.

Answer: A. Point mutation of the 23S rRNA binding site; no other class attacks the initiation step, so resistance has to arise independently

Mutations in the 23S rRNA genes reshape the ribosomal target and are the classic escape route, described in enterococci and staphylococci exposed for long periods. Because the drug acts at a step nothing else targets, an organism already resistant to macrolides, lincosamides or aminoglycosides is not expected to arrive resistant to this class as well. That is exactly the property stewardship protects by reserving the drug and keeping courses short.